If CJC-1295 is the slow burn, ipamorelin is the spark. The two peptides are frequently discussed together — and prescribed together — because they work through complementary mechanisms to support growth hormone secretion.
Understanding what ipamorelin actually does, and what makes it distinct, helps clarify why the combination has attracted so much clinical interest.
Ipamorelin is a synthetic pentapeptide — five amino acids — that acts as a selective ghrelin receptor agonist. Ghrelin is often called the "hunger hormone," but it also plays a significant role in growth hormone regulation. By binding to ghrelin receptors in the pituitary gland, ipamorelin triggers a pulse of growth hormone release.
What sets ipamorelin apart from other peptides in this class is its selectivity. A landmark 1998 study published in the European Journal of Endocrinology identified ipamorelin as the first growth hormone secretagogue with a selectivity for GH release comparable to GHRH — meaning it stimulates GH without meaningfully elevating cortisol or prolactin, two hormones that other peptides in this class tend to raise as an unwanted side effect.
That selectivity is significant. Elevated cortisol is associated with muscle breakdown, fat accumulation, and immune suppression. A GH-releasing peptide that avoids those effects is a meaningfully different therapeutic tool.
CJC-1295 works through the GHRH pathway — it tells the pituitary to stay primed for GH release over a sustained period. Ipamorelin works through the ghrelin receptor pathway — it triggers an acute GH pulse. Together, the two peptides work on complementary GH-releasing mechanisms simultaneously, which practitioners believe produces a more robust and physiologically appropriate GH response than either peptide alone.
Think of it as sustained readiness (CJC-1295) combined with targeted activation (ipamorelin).
Ipamorelin has been studied in animal models and in limited human pharmacokinetic research. A 1999 study modeled ipamorelin's GH-releasing properties in healthy adults, confirming dose-dependent GH release with a short half-life of approximately two hours — consistent with its role as an acute GH pulse stimulator.
Its animal data includes research on bone growth, fat metabolism, and GH deficiency models. As with most peptides in this cluster, large-scale human clinical outcome trials are limited.
Ipamorelin is currently not legally available through licensed compounding pharmacies in the United States. Like the other peptides on the expected reclassification list, it remains on the FDA's Category 2 restricted list until the formal update is published. The February 2026 announcement indicates it's expected to return — but that regulatory step hasn't been completed yet.
Once reclassified, ipamorelin will again be available through licensed compounding pharmacies under physician prescription. Until then, sourcing it through unregulated channels carries quality and legal risks that aren't worth taking.
Belle currently offers a range of provider-guided programs that are available right now. If you're curious about what's available today while the peptide landscape evolves, we're a good starting point.
Explore Belle's currently available programs.
Sources
Belle offers provider-guided compounded medication programs. Peptide compounds are not FDA-approved drugs. Access requires a licensed provider's prescription. Always work with a qualified medical professional before beginning any new therapy.
